T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic 13 Nov Written by Alexandra Collingbourne Alexandra Collingbourne Previous Previous ACF Investors: Why raising EIS limits is a budget imperative Next Next Paying it forward: The trailblazing Cambridge entrepreneurs engineering the next wave of global innovators
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic 13 Nov Written by Alexandra Collingbourne Alexandra Collingbourne
